NCT05364307

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,555 (actual)
• Sponsor: Global Alzheimer's Platform Foundation · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment
• Memory Loss
• Memory Disorders
• Memory Impairment

Interventions

Type	Name	Description
OTHER	Prescreener database	Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.

Timeline

• Start date: 2022-06-13
• Primary completion: 2025-01-31
• Completion: 2025-01-31
• First posted: 2022-05-06
• Last updated: 2025-02-05

Locations

19 sites across 2 countries: United States, Canada